CoChat

Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis

King, Jordan B., Sainski-Nguyen, Amy M., Bellows, Brandon K. · 2016 · Journal of Pain & Palliative Care Pharmacotherapy

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

The objective of this analysis was to compare the cost-effectiveness of clinic-based methadone maintenance therapy (MMT) and office-based buprenorphine maintenance therapy (BMT) from the perspective of third-party payers in the United States. The authors used a Markov cost-effectiveness model. A hypothetical cohort of 1000 adult, opioid-dependent patients was modeled over a 1-year time horizon. Patients were allowed to transition between the health states of in opioid dependence treatment and either abusing or not abusing opioids, or to have dropped out of treatment. Probabilities were derived from randomized clinical trials comparing methadone and buprenorphine. Costs included drug and administration, clinic visits, and therapy sessions. Effectiveness outcomes examined were (1) retention in the treatment program and (2) opioid abuse-free weeks. For retention in treatment at 1 year, MMT was more costly ($4,613 vs. $4,155) and more effective (20.3% vs. 15.9%) than BMT, resulting in an incremental cost-effectiveness ratio (ICER) of $10,437 per additional patient retained in treatment. MMT was also more effective than BMT in terms of opioid abuse-free weeks (9.2 vs. 9.1 weeks), resulting in an ICER of $8,515 per opioid abuse-free week gained. One-way sensitivity analyses found costs per week of MMT to have the largest impact on the retention-in-treatment outcome, whereas the probability of dropping out with MMT had the greatest impact on opioid abuse-free weeks. The authors conclude that MMT is cost-effective compared with BMT for the treatment of patients with opioid dependence. However, the treatment of substance abuse is complex, and decision makers should also consider individual patient characteristics when making coverage decisions.

Overview

Integrity signals

Registry

Crossref · 10.3109/15360288.2015.1135847

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 24 references

Research works printed but not linked: 8

  1. MMWR Morb Mort Wkly Rep., 60, 1487
  2. Baser O, Am J Manag Care., 17, S235
  3. Connock M, Health Technol Assess., 11, 1
  4. Strain EC, Am J Psychiatry., 151, 1025
  5. Substance Abuse and Mental Health Services Administration, Methadone Clinics by County Locations
  6. Center for Substance Abuse and Treatment, SAMHSA/CSAT Treatment Improvement Protocols.Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction
  7. Center for Substance Abuse and Treatment, Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs
  8. World Health Organization, WHO Collaborative Study on Substitution Therapy of Opioid Dependence and HIV/AIDS

Cited by

See all 20

Metadata

Authors
King, J. B., Sainski-Nguyen, A. M., & Bellows, B. K.
Corresponding author
King, Jordan B.
Venue
Journal of Pain & Palliative Care Pharmacotherapy
Published
2016-01-02
Volume
30
Issue
1
Pages
55-65
ISSN
  • 1536-0288 (ISSN-L)
  • 1536-0539
OpenAlex
W2329484547
Cited by
20
References
24
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 1 · 2017: 2
FWCI
0.99
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Pain & Palliative Care Pharmacotherapy (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Drug Abuse
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
opioid use disorder, methadone maintenance treatment, office-based opioid treatment, cost-effectiveness, treatment retention, third-party payers
MeSH terms
Adult, Ambulatory Care Facilities, Buprenorphine, Cost-Benefit Analysis, Humans, Markov Chains, Methadone, Opioid-Related Disorders, United States, Randomized Controlled Trials as Topic, Opiate Substitution Treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.3109/15360288.2015.1135847
The paper
King, J. B., Sainski-Nguyen, A. M., & Bellows, B. K. (2016). Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis. Journal of Pain & Palliative Care Pharmacotherapy. https://doi.org/10.3109/15360288.2015.1135847

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.